Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Scynexis Inc (SCYX)

Scynexis Inc (SCYX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 69,067
  • Shares Outstanding, K 32,579
  • Annual Sales, $ 13,160 K
  • Annual Income, $ -32,870 K
  • 60-Month Beta 2.04
  • Price/Sales 5.20
  • Price/Cash Flow N/A
  • Price/Book 1.56
Trade SCYX with:

Options Overview Details

View History
  • Implied Volatility 76.53% ( -30.28%)
  • Historical Volatility 110.78%
  • IV Percentile 4%
  • IV Rank 6.41%
  • IV High 245.07% on 05/18/22
  • IV Low 64.99% on 04/07/22
  • Put/Call Vol Ratio 4.00
  • Today's Volume 5
  • Volume Avg (30-Day) 91
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 5,765
  • Open Int (30-Day) 6,334

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.56
  • Number of Estimates 1
  • High Estimate -0.56
  • Low Estimate -0.56
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -154.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.81 +14.36%
on 05/12/22
2.76 -25.00%
on 05/03/22
-0.26 (-11.16%)
since 04/22/22
3-Month
1.81 +14.36%
on 05/12/22
5.15 -59.79%
on 03/23/22
-1.98 (-48.89%)
since 02/23/22
52-Week
1.81 +14.36%
on 05/12/22
10.25 -79.80%
on 06/01/21
-6.54 (-75.96%)
since 05/21/21

Most Recent Stories

More News
SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference

JERSEY CITY, N.J., May 20, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome...

SCYX : 2.07 (-2.36%)
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates

Scynexis (SCYX) delivered earnings and revenue surprises of 31.08% and 1.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

SCYX : 2.07 (-2.36%)
VVOS : 1.3300 (-6.34%)
SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

Data show that of the FURI study patients with refractory or relapsed vulvovaginal candidiasis (VVC) treated with ibrexafungerp, 71.4% had successful...

SCYX : 2.07 (-2.36%)
SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

Product theater presentation will be held on May 7 to highlight clinical data and attributes of the first new antifungal class approved in more than 25...

SCYX : 2.07 (-2.36%)
SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases

New interim analysis of the Phase 3 CARES study showed complete or partial response in 78% of the 18 patients treated with ibrexafungerp for infections...

SCYX : 2.07 (-2.36%)
SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

JERSEY CITY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten...

SCYX : 2.07 (-2.36%)
SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten public offering of...

SCYX : 2.07 (-2.36%)
SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

Data reinforce findings from previous analyses demonstrating oral ibrexafungerp’s potential to combat difficult-to-treat and refractory fungal infections...

SCYX : 2.07 (-2.36%)
SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

JERSEY CITY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced that it has commenced an underwritten public offering...

SCYX : 2.07 (-2.36%)
SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, Portugal

Data from studies evaluating ibrexafungerp in serious fungal infections will be presented...

SCYX : 2.07 (-2.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening...

See More

Key Turning Points

3rd Resistance Point 2.23
2nd Resistance Point 2.19
1st Resistance Point 2.13
Last Price 2.07
1st Support Level 2.03
2nd Support Level 1.99
3rd Support Level 1.93

See More

52-Week High 10.25
Fibonacci 61.8% 7.03
Fibonacci 50% 6.03
Fibonacci 38.2% 5.03
Last Price 2.07
52-Week Low 1.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar